Trevogrumab

Trevogrumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1429201-24-0
PubChem
DrugBank
ChemSpider	none
KEGG	D11242

Trevogrumab (INN<ref name=WHOList113>World Health Organization,

 International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113, 
 WHO Drug Information, 
 2015,
 Vol. 29(Issue: 2),
 
 
 
 
 
 Full text,</ref>) (REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.

This drug was developed by Regeneron Pharmaceuticals, Inc.<ref>Statement On A Nonproprietary Name Adopted By The USAN Council - Trevogrumab, American Medical Association.</ref>

References

<references/>

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

   This article is a medical stub. You can help WikiMD by expanding it!